Continuing Education Activity

Oxazepam is a short- to intermediate-acting benzodiazepine used for the treatment of alcohol withdrawal and the management of anxiety disorders. Oxazepam is approved by the US Food and Drug Administration (FDA) for anxiety disorders, short-term relief of anxiety symptoms, and anxiety associated with major depressive disorder. Clinicians should monitor patients receiving oxazepam for changes in cardiovascular and respiratory status, hemodynamic stability, and mental status. In cases of suspected toxicity, prompt stabilization of airway, breathing, and circulation is essential, and advanced airway management may be required in severe cases.

This activity reviews the mechanism of action of oxazepam, along with its dosing, pharmacokinetics, adverse effects, contraindications, boxed warnings, monitoring, clinical toxicology, and potential drug–drug interactions. This activity also reviews the pharmacology of oxazepam to help clinicians tailor treatment plans to individual patient needs and make informed therapeutic decisions. In addition, this activity provides healthcare professionals with essential knowledge and tools to support safe and effective oxazepam administration and improve patient outcomes. The activity also emphasizes the roles of evidence-based medicine and interprofessional collaboration in optimizing treatment regimens, minimizing adverse effects, and enhancing overall patient care for oxazepam therapy.

Objectives:

• Identify the approved indications, pharmacologic mechanism, and pharmacokinetic properties of oxazepam relevant to clinical use.
• Assess patients receiving oxazepam for adverse effects, toxicity, withdrawal symptoms, and changes in cardiovascular or respiratory status.
• Apply evidence-based strategies to reduce the risk of misuse, dependence, and drug–drug interactions associated with oxazepam therapy.
• Collaborate with the interprofessional healthcare team to support safe prescribing of oxazepam, improving treatment efficacy and patient outcomes for those who may benefit from oxazepam therapy.

Indications

Oxazepam is classified as a short- to intermediate-acting benzodiazepine. The effectiveness of the drug for long-term use (ie, more than 4 months) has not been established in clinical studies. Under the Convention on Psychotropic Substances, oxazepam is classified as a Schedule IV substance, indicating a lower potential for abuse compared with Schedule III substances such as ketamine.[1]

FDA-Approved Indications

Oxazepam is a benzodiazepine approved by the US Food and Drug Administration (FDA) for the treatment of alcohol withdrawal and the management of anxiety disorders.[2] According to the product labeling, oxazepam is indicated for anxiety disorders and for the short-term relief of anxiety.[3] The drug is also indicated for anxiety associated with major depressive disorder.[4]

The American Society of Addiction Medicine notes that for alcohol use disorder (AUD), benzodiazepines are first-line pharmacotherapy because of their well-documented effectiveness in decreasing withdrawal symptoms, including seizures and delirium.[5] The American Psychiatric Association recommends that benzodiazepines be used in patients with AUD only for the management of acute alcohol withdrawal syndrome. According to the American Psychiatric Association, the primary role of benzodiazepines in AUD is for alcohol detoxification and withdrawal management.

Off-Label Uses

Oxazepam has several off-label uses, including confusional arousals, sleep terrors, social phobia, post-traumatic stress disorder, insomnia, premenstrual dysphoric disorder, catatonia, and tinnitus.[6] Oxazepam can also be used to manage perioperative anxiety.[7]

Currently, oxazepam is not FDA-approved for use in children aged 6 or younger due to the risk of respiratory arrest. In some cases, the drug may be considered for patients who have difficulty maintaining sleep, in contrast to medications that primarily aid with sleep initiation.[8][9]

Mechanism of Action

Benzodiazepines are among the most commonly prescribed medications for the treatment of insomnia and anxiety. Lorazepam, oxazepam, and temazepam bypass Phase I oxidative metabolism by the cytochrome P450 (CYP450) system and are metabolized by Phase II glucuronidation. This process forms water-soluble, inactive metabolites that are excreted renally. This pathway is clinically significant because glucuronidation remains relatively preserved in patients with hepatic impairment or cirrhosis. Consequently, oxazepam carries a lower risk of drug accumulation and prolonged sedation compared with longer-acting drugs such as diazepam. For this reason, these agents are often preferred in older adults and in patients with liver disease to reduce the risk of metabolic complications.[10]

Benzodiazepines bind to gamma-aminobutyric acid (GABA)-A receptors, which are ligand-gated chloride ion channels that mediate synaptic inhibition in the central nervous system (CNS). Benzodiazepines bind as allosteric modulators and increase the frequency of chloride ions crossing the cell membrane. Once benzodiazepines bind to the GABA receptor, they change conformation and exhibit increased affinity for GABA. This conformational change increases the frequency of chloride ion channel opening and, subsequently, hyperpolarization of the neuronal cell membrane occurs, resulting in a decreased firing rate at the synapse.[1] In contrast, barbiturates increase GABA-A receptor facilitation by prolonging the duration of chloride channel opening.[11][12] 

Benzodiazepines are the preferred drugs for the treatment of alcohol withdrawal syndrome because they help prevent serious issues such as seizures during withdrawal. Long-acting benzodiazepines, such as diazepam and chlordiazepoxide, are commonly used because they provide a smoother withdrawal process with fewer breakthrough or rebound symptoms. Intermediate-acting benzodiazepines, such as lorazepam and oxazepam, that are metabolized by the kidneys, are considered safer options and are preferred in patients with alcoholic liver disease.[13]

Pharmacokinetics

Absorption: Oxazepam has a rapid onset of action, with peak plasma concentration levels (Cmax) occurring approximately 3 hours after dosing (Tmax). 

Distribution: Plasma protein binding is approximately 89%, likely to albumin.

Metabolism: Oxazepam is a short-acting benzodiazepine that is metabolized in the liver by glucuronidation into inactive metabolites. Oxazepam is a preferred drug in patients with hepatic impairment and has no active metabolites.[14]

Excretion: Oxazepam has an elimination half-life ranging from 3 to 21 hours and is primarily excreted via the renal pathway. Oxazepam is not subject to CYP450 interactions and does not accumulate with CYP inhibition.[15]

Administration

Available Dosage Forms and Strengths

Oxazepam is administered orally as capsules of 10 mg, 15 mg, or 30 mg, and as a 15 mg tablet. The medication can be taken without regard to meals. Dose adjustment is generally not required in patients with hepatic or renal impairment; however, caution is advised in patients with renal impairment.[16]

Dosage

For anxiety:

• In adults with mild to moderate anxiety, 10 to 15 mg oxazepam is administered orally every 6 to 8 hours, with a maximum daily dose of 120 mg.
• In adults with severe anxiety or agitation, 15 to 30 mg oxazepam is administered orally every 6 to 8 hours.
• In children aged 6 to 12, clear dosing guidelines are not established; however, clinicians may administer approximately 1 mg/kg/d orally, divided equally into 3 doses.
• In geriatric populations, 10 to 15 mg oxazepam is initially administered orally 3 or 4 times daily, with cautious dose increases if necessary. The recommended maximum dosage is 60 mg/d. 

For alcohol withdrawal:

• In adults, oxazepam 15 mg is administered orally 3 times daily.

Specific Patient Populations

Hepatic impairment: Oxazepam, similar to other benzodiazepines, is rarely associated with elevations in serum aminotransferases, such as alanine aminotransferase or alkaline phosphatase, during therapy. When such laboratory abnormalities occur, they are typically mild, transient, and not associated with clinical symptoms. Clinically apparent liver injury attributable to oxazepam is extremely rare. Despite its long history of clinical use, no well-documented cases of symptomatic, acute liver injury directly caused by oxazepam have been reported in the medical literature. As a class precaution, the product labeling for oxazepam includes warnings regarding the potential for hepatic dysfunction and jaundice; however, these warnings are precautionary.[17]

Renal impairment: In a multiple-dose study of oxazepam in patients with renal impairment, steady-state concentrations of unbound oxazepam were similar to those in control subjects.[18] Oxazepam is metabolized by direct hepatic glucuronidation and is eliminated predominantly in the urine (83%–92%), with minimal susceptibility to CYP450-mediated interactions.

In chronic renal failure, total plasma concentrations may decrease; however, an increased unbound fraction maintains the pharmacologic effect. Inactive glucuronide metabolites may accumulate. Routine dose adjustment is generally not required, but clinical monitoring for excessive sedation is recommended, particularly in patients with advanced renal dysfunction or in frail individuals.[19]

Pregnancy considerations: Benzodiazepine use near delivery may result in floppy infant syndrome, which is characterized by hypothermia, lethargy, inadequate respiratory effort, and feeding difficulties, and is associated with maternal use of benzodiazepines shortly before delivery.[20] Benzodiazepines should not be utilized in pregnancy unless necessary for the acute treatment of severe anxiety or agitation.[21] If discontinuation of benzodiazepines is considered during pregnancy, they should not be discontinued abruptly. Neonatal withdrawal syndromes have been reported and may include restlessness, hypertonia, hyperreflexia, diarrhea, and vomiting, have been described in infants.

In this nationwide cohort study of 1,516,846 children, prenatal exposure to benzodiazepines was not associated with increased risks of autism spectrum disorder or attention-deficit hyperactivity disorder after adjustment for familial and genetic confounding. Although conventional analyses showed modest associations, these findings were attenuated to null in sibling-comparison models. Results were consistent across all trimesters of exposure and for short-acting and long-acting benzodiazepines. The findings suggest that previously reported neurodevelopmental risks are more likely attributable to maternal or familial factors rather than a causal effect of benzodiazepine exposure.[22][23] Healthcare professionals may register patients by contacting the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388. 

Breastfeeding considerations: Oxazepam is present in low concentrations in breast milk, has a relatively short elimination half-life, and carries a low risk of adverse effects during breastfeeding at usual maternal doses. Available safety classification systems consider oxazepam compatible with breastfeeding.[24] Although routine avoidance is not required, infants should be monitored for excessive sedation, poor feeding, and inadequate weight gain. Breastfeeding patients should be advised to notify their healthcare provider and to seek medical attention if concerning infant symptoms occur.[25] 

Pediatric patients: The safety and efficacy of oxazepam in pediatric patients aged 6 or younger have not been documented.

Older patients: The 2023 American Geriatrics Society (AGS) Beers Criteria identifies benzodiazepines, including oxazepam, as potentially inappropriate medications for older adults. Their use is discouraged because of the increased risk of delirium, cognitive impairment, falls, fractures, and motor vehicle accidents in this population. However, the AGS notes that benzodiazepines may be appropriate for certain conditions, including seizure disorders, periprocedural sedation, severe generalized anxiety disorder, REM sleep behavior disorder, and alcohol withdrawal.

Because older adults are at increased risk of adverse effects such as oversedation, disorientation, ataxia, and falls with higher doses of benzodiazepines, treatment with oxazepam should be initiated at a lower dose in individuals aged 65 and older.[26][27][28] Oxazepam is generally not necessary to titrate oxazepam. The recommendation is to use the lowest effective dose possible for the shortest reasonable timeframe.

Adverse Effects

Common adverse effects associated with benzodiazepines such as oxazepam may include sedation, fatigue, depression, confusion, memory impairment, dizziness, ataxia, slurred speech, hyper-excitability, nervousness, and weakness. Less frequently encountered adverse effects may involve hypotension, hallucinations, mania, dry mouth, hypersalivation, edema, leukopenia, decreased libido, incontinence, rash, menstrual irregularities, jaundice, and diplopia. Severe adverse effects of oxazepam include respiratory depression and neonatal abstinence syndrome. Anterograde amnesia also has correlations with benzodiazepine use.[29]

Several cases of fixed drug eruptions, which present clinically as well-demarcated oval macules, have been reported in patients taking oxazepam. In these cases, urticaria and diffuse exanthems were not observed.[30] Infrequent cases of QTc prolongation and torsades de pointes have been reported in a retrospective analysis of the postmarketing study; additional research is required.[31]

Drug-Drug interactions

• Patients taking oxazepam for insomnia should avoid caffeine-containing products as they may decrease the efficacy of the drug. Coadministering oxazepam with other CNS depressants such as diphenhydramine or hydrocodone may result in enhancement of CNS effects (eg, severe sedation and respiratory depression). Oxazepam is also not recommended for patients with sleep apnea.[32]

• Concurrent use of opioid agonists such as methadone, morphine, and naltrexone may result in respiratory depression, severe hypotension, and sedation, which is discussed in the box warnings in the Contraindications section.[33]

• The concomitant administration of temazepam with alcohol or other CNS depressants can lead to significant drowsiness, respiratory depression, unconsciousness, and even fatality. Remaining effects on psychomotor and cognitive abilities may result in impaired driving ability and potentially higher risks of falling and hip fractures. Furthermore, the pharmacological activity of oxapeam can be increased by the concurrent use of barbiturates, antipsychotics, skeletal muscle relaxants, and antihistamines.[34][35]

Contraindications

The absolute contraindication, as per the manufacturer's information, is hypersensitivity to oxazepam or any excipients.[36][37]

FDA-Issued Box Warnings

• Concurrent use with opioids: Concomitant administration of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Concomitant prescribing should be reserved for patients for whom alternative treatment options are inadequate, with dose and duration limited to the minimum required and close monitoring for sedation and respiratory depression.[33]

• Abuse, misuse, and addiction: Benzodiazepines, including oxazepam, are associated with risks of abuse, misuse, and addiction, which may lead to overdose or death. The risk is increased with concurrent use of alcohol, other CNS depressants, or illicit substances. Assessment of misuse risk should be conducted before initiation of therapy and periodically during treatment.[38][39]

• Dependence and withdrawal: Continued use of benzodiazepines, including oxazepam, may result in clinically significant physical dependence. Abrupt discontinuation or rapid dose reduction following prolonged use may precipitate acute and potentially life-threatening withdrawal reactions. Dosage reduction or discontinuation should be achieved through a gradual taper.[40]

Warnings and Precautions

• The use of oxazepam is generally not recommended in older adults because of the increased risk of dependence, cognitive impairment, and falls. Several studies have suggested that long-term use of benzodiazepines, including oxazepam, may be associated with an increased risk of dementia in older patients; therefore, clinicians should exercise caution when prescribing oxazepam in the geriatric population.[41][42]

• Oxazepam may also cross the placenta and be excreted into breastmilk; thus, it is not a recommended pharmaceutical therapy in pregnant or nursing women. According to the prior system of FDA categorization of the safety of medications during pregnancy, there is evidence of risk to the fetus when using benzodiazepines during pregnancy. In some instances, potential benefits may still justify use. In mothers receiving benzodiazepines during pregnancy, neonatal flaccidity, as well as withdrawal symptoms, may be present.[43]

• Patients who have demonstrated hypersensitivity to previous oxazepam use or other benzodiazepines should not take oxazepam. Also, patients with substance misuse disorders should not be prescribed oxazepam except for short-term emergencies or urgencies. As per American Heart Association guidelines, this is applicable especially in the setting of cocaine use, where benzodiazepines can be used in the setting of substance use (cocaine) to relieve chest pain and have beneficial cardiac hemodynamic effects.[44]

Monitoring

In patients receiving oxazepam, cardiovascular and respiratory status, as well as hemodynamic stability and vital signs, should be monitored. Adverse effects, overdose, and toxicity from benzodiazepines may mimic other clinical conditions, particularly with long-term use. Therefore, appropriate laboratory tests, such as a complete blood count, blood urea nitrogen, creatinine, and other relevant serum studies, may be obtained when clinically indicated.

Patients undergoing alcohol withdrawal should be monitored using the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) protocol, most commonly the CIWA for Alcohol-Revised (CIWA-Ar) score.[45] Healthcare professionals can use the prescription drug monitoring program to identify potential misuse.[46] Although benzodiazepines are not first-line therapy for anxiety disorders, monitoring treatment response is important when they are used for severe anxiety. The Generalized Anxiety Disorder 7-item (GAD-7) scale can be used to assess the severity of GAD. This GAD-7 tool generates a score ranging from 0 to 21 and is categorized as minimal (0-4), mild (5-9), moderate (10-14), or severe (≥15), which is useful for screening and monitoring treatment response.[3]

Toxicity

Signs and Symptoms of Overdose

A patient with oxazepam overdose typically presents with normal vital signs and severe CNS depression. Clinical symptoms may include ataxia, slurred speech, confusion, drowsiness, and lethargy. Comatose patients are also commonly seen with severe toxicity. Respiratory compromise most commonly occurs when patients intentionally ingest benzodiazepines with another sedative agent, such as an opioid. Oxazepam is the least sedating drug among all benzodiazepines due to slower absorption.[47][48][49] 

According to the American Heart Association 2023 guidelines, isolated benzodiazepine poisoning rarely results in life-threatening respiratory depression or hemodynamic instability. Therefore, clinicians should consider the possibility of concomitant opioid, alcohol, or other CNS depressant exposure in such cases of poisoning.[50] Respiratory arrest can occur with rapid intravenous (IV) injection or misuse of benzodiazepines via the IV route, particularly when combined with other CNS depressants such as opioids.[51]

Management of Overdose

If toxicity is suspected, rapid, immediate maintenance of airway, breathing, and circulation must be provided. Intubation may be necessary if there is a severe compromise.

If an isolated oxazepam overdose is suspected in a patient with stable hemodynamics and an otherwise unremarkable physical examination, monitoring of vital signs and clinical observation are generally appropriate.

Patients who exhibit respiratory compromise due to oxazepam toxicity may have also taken another drug, such as an opioid. Therefore, it may be appropriate to administer naloxone. Clinicians may administer flumazenil, a competitive benzodiazepine receptor antagonist, to reverse an overdose. However, the administration may precipitate withdrawal seizures in patients who chronically use benzodiazepines and have developed tolerance.[52][53]

Enhancing Healthcare Team Outcomes

Oxazepam is a commonly prescribed benzodiazepine with potential for misuse; therefore, treating patients requires an interprofessional approach. Physicians, nurse practitioners, physician assistants, nurses, pharmacists, and laboratory personnel all contribute to safe and effective care. The healthcare team should closely monitor patients receiving oxazepam for changes in hemodynamic status, including respiratory compromise, as well as alterations in mental status such as stupor, somnolence, or confusion. Early recognition of adverse effects or signs of toxicity is essential.

Nurses play a key role in monitoring patients and recognizing toxicity, as well as promptly communicating concerning findings to the prescribing clinician. Collaboration between prescribers and pharmacists is also important for minimizing medication-related risks. Prescription drug monitoring programs, such as the Controlled Substance Utilization Review and Evaluation System (CURES), can help identify potential misuse and improve patient safety.[54] Pharmacists may also help reduce the risk of drug–drug interactions, particularly in patients receiving opioids from other providers. In cases of overdose, the emergency medicine team should rapidly stabilize the patient and evaluate for possible polysubstance ingestion. Psychiatric consultation is appropriate when overdose is intentional, and addiction medicine consultation may be beneficial for patients undergoing alcohol withdrawal.[5] Overall, coordinated interprofessional care supports safer oxazepam use and improved patient outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Howland RH. Safety and Abuse Liability of Oxazepam: Is This Benzodiazepine Drug Underutilized? J Psychosoc Nurs Ment Health Serv. 2016 Apr;54(4):22-5. [PubMed: 27042924]

2.

Bahji A, Bach P, Danilewitz M, Crockford D, El-Guebaly N, Devoe DJ, Saitz R. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction. 2022 Oct;117(10):2591-2601. [PMC free article: PMC9969997] [PubMed: 35194860]

3.

Beyer C, Currin CB, Williams T, Stein DJ. Meta-analysis of the comparative efficacy of benzodiazepines and antidepressants for psychic versus somatic symptoms of generalized anxiety disorder. Compr Psychiatry. 2024 Jul;132:152479. [PubMed: 38564872]

4.

Wang C, Wang X, Wang J, Li X, Lu D, Guo F, Yao Y, Zhu J, Shen C, Xie Q, Mao H, Zhang P, Yang X, Wu H, Lv Q, Yi Z. Prevalence and clinical correlates of benzodiazepine use in the patients with major depressive disorder. J Affect Disord. 2024 Oct 15;363:619-625. [PubMed: 39043307]

5.

The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020 May/Jun;14(3S Suppl 1):1-72. [PubMed: 32511109]

6.

Jufas NE, Wood R. The use of benzodiazepines for tinnitus: systematic review. J Laryngol Otol. 2015 Jul;129 Suppl 3:S14-22. [PubMed: 25858126]

7.

Ge FZ, Zhao K, Au E, Sadeghirad B, Fournier R, Belley-Côté E, Young J, Wang E, Beaver C, Kloppenburg S, Mazer D, Jacobsohn E, Verret M, Spence J. Effects of perioperative benzodiazepine administration on postoperative patient-reported outcomes: a systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2025 Dec;135(6):1741-1752. [PMC free article: PMC12799406] [PubMed: 41152051]

8.

Singh I, Oosthuizen F. A retrospective review on benzodiazepine use: A case study from a chronic dispensary unit. S Afr Med J. 2019 Jan 31;109(2):127-132. [PubMed: 30834865]

9.

Hok L, BoŽičević L, Sremec H, Šakić D, Vrček V. Racemization of oxazepam and chiral 1,4-benzodiazepines. DFT study of the reaction mechanism in aqueous solution. Org Biomol Chem. 2019 Feb 06;17(6):1471-1479. [PubMed: 30676597]

10.

Dinis-Oliveira RJ. Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463. [PubMed: 28903606]

11.

Goldschen-Ohm MP. Benzodiazepine Modulation of GABA_A Receptors: A Mechanistic Perspective. Biomolecules. 2022 Nov 30;12(12) [PMC free article: PMC9775625] [PubMed: 36551212]

12.

Bianchi MT, Botzolakis EJ, Lagrange AH, Macdonald RL. Benzodiazepine modulation of GABA(A) receptor opening frequency depends on activation context: a patch clamp and simulation study. Epilepsy Res. 2009 Aug;85(2-3):212-20. [PMC free article: PMC2834588] [PubMed: 19447010]

13.

Chand PK, Panda U, Mahadevan J, Murthy P. Management of Alcohol Withdrawal Syndrome in Patients with Alcoholic Liver Disease. J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1527-1534. [PMC free article: PMC9630022] [PubMed: 36340306]

14.

Miyake T, Fujita Y, Hirabayashi M, Komiyama N, Morita K, Tachibana T, Terao K. Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice. Drug Metab Dispos. 2025 Apr;53(4):100050. [PubMed: 40054035]

15.

de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol. 2003 Mar;6(1):57-72. [PubMed: 12899737]

16.

Furlan V, Demirdjian S, Bourdon O, Magdalou J, Taburet AM. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999 May;289(2):1169-75. [PubMed: 10215701]

17.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 22, 2023. Oxazepam. [PubMed: 31643434]

18.

Greenblatt DJ. Hepatic Clearance of Drugs in Patients With Renal Insufficiency. Clin Pharmacol Drug Dev. 2013 Oct;2(4):295-7. [PubMed: 27121933]

19.

Busch U, Molzahn M, Bozler G, Koss FW. Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease. Arzneimittelforschung. 1981;31(9):1507-11. [PubMed: 7197965]

20.

Wang X, Zhang T, Ekheden I, Chang Z, Hellner C, Jan Hasselström, Jayaram-Lindström N, M D'Onofrio B, Larsson H, Mataix-Cols D, Sidorchuk A. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: A systematic review. Neurosci Biobehav Rev. 2022 Jun;137:104647. [PubMed: 35367514]

21.

Vickery PB. Concepts for selection and utilization of psychiatric medications in pregnancy. Ment Health Clin. 2023 Dec;13(6):255-267. [PMC free article: PMC10696173] [PubMed: 38058594]

22.

Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of Prenatal Exposure to Benzodiazepines With Development of Autism Spectrum and Attention-Deficit/Hyperactivity Disorders. JAMA Netw Open. 2022 Nov 01;5(11):e2243282. [PMC free article: PMC9682429] [PubMed: 36413366]

23.

Puia-Dumitrescu M, Comstock BA, Li S, Heagerty PJ, Perez KM, Law JB, Wood TR, Gogcu S, Mayock DE, Juul SE., PENUT Consortium. Assessment of 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants Receiving Opioids and Benzodiazepines. JAMA Netw Open. 2021 Jul 01;4(7):e2115998. [PMC free article: PMC8264640] [PubMed: 34232302]

24.

Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. 2021 Jan-Feb 01Am J Ther. 28(1):e118-e126. [PubMed: 30601177]

25.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Feb 15, 2026. Oxazepam. [PubMed: 30000303]

26.

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PMC free article: PMC12478568] [PubMed: 37139824]

27.

Karki S, Thapa RB, Shrestha R. Exploring Potentially Inappropriate Medication Use on Elderly Patients in a General Medicine Ward Using 2023 AGS Beers Criteria. Aging Med (Milton). 2025 Jun;8(3):238-248. [PMC free article: PMC12226411] [PubMed: 40620508]

28.

Choo A. Potentially inappropriate medicines for older people: consensus-based lists. Aust Prescr. 2025 Aug;48(4):128-132. [PMC free article: PMC12377978] [PubMed: 40861405]

29.

Martinez L, Vorspan F, Declèves X, Azuar J, Fortias M, Questel F, Dereux A, Grichy L, Barreteau H, Bellivier F, Lépine JP, Bloch V. An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen. Fundam Clin Pharmacol. 2018 Apr;32(2):200-205. [PubMed: 29224234]

30.

Krischer J, Prins C, Ruffieux P, Kondo-Oestreicher M, Saurat JH. Extensive fixed drug eruption induced by oxazepam. Arch Dermatol. 1996 Jun;132(6):718. [PubMed: 8651735]

31.

Ali Z, Ismail M, Rehman IU, Goh KW, Razi P, Ming LC. Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System. J Pharm Policy Pract. 2024;17(1):2399716. [PMC free article: PMC11407426] [PubMed: 39291052]

32.

Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015 Oct;49(4):493-501. [PubMed: 26143953]

33.

Liu Y, Hong Q, Xie X, Shen W, Chen W, Liu H, Zhou W. Benzodiazepine Use Among Individuals with Opioid Use Disorder: A Narrative Review. Subst Abuse Rehabil. 2025;16:283-291. [PMC free article: PMC12553388] [PubMed: 41142836]

34.

Pham Nguyen TP, Soprano SE, Hennessy S, Brensinger CM, Bilker WB, Miano TA, Acton EK, Horn JR, Chung SP, Dublin S, Oslin DW, Wiebe DJ, Leonard CE. Population-based signals of benzodiazepine drug interactions associated with unintentional traumatic injury. J Psychiatr Res. 2022 Jul;151:299-303. [PMC free article: PMC9513701] [PubMed: 35526445]

35.

Geulayov G, Ferrey A, Casey D, Wells C, Fuller A, Bankhead C, Gunnell D, Clements C, Kapur N, Ness J, Waters K, Hawton K. Relative toxicity of benzodiazepines and hypnotics commonly used for self-poisoning: An epidemiological study of fatal toxicity and case fatality. J Psychopharmacol. 2018 Jun;32(6):654-662. [PubMed: 29442611]

36.

Wang L, Varghese S, Bassir F, Lo YC, Ortega CA, Shah S, Blumenthal KG, Phillips EJ, Zhou L. Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne). 2022;9:949520. [PMC free article: PMC9449801] [PubMed: 36091694]

37.

Ancuceanu R, Dinu M, Furtunescu F, Boda D. An inventory of medicinal products causing skin rash: Clinical and regulatory lessons. Exp Ther Med. 2019 Dec;18(6):5061-5071. [PMC free article: PMC6880410] [PubMed: 31798726]

38.

Licata SC, Rowlett JK. Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav. 2008 Jul;90(1):74-89. [PMC free article: PMC2453238] [PubMed: 18295321]

39.

Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012 Sep 01;125(1-2):8-18. [PMC free article: PMC3454351] [PubMed: 22857878]

40.

Brunner E, Chen CA, Klein T, Maust D, Mazer-Amirshahi M, Mecca M, Najera D, Ogbonna C, Rajneesh KF, Roll E, Sanders AE, Snodgrass B, VandenBerg A, Wright T, Boyle M, Devoto A, Framnes-DeBoer S, Kleykamp B, Norrington J, Lindsay D., Clinical Guideline Committee (CGC) Members. ASAM Staff and Contractors. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. J Gen Intern Med. 2025 Sep;40(12):2814-2859. [PMC free article: PMC12463801] [PubMed: 40526204]

41.

Flint AJ. Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22(2):101-14. [PubMed: 15733018]

42.

Novais T, Garnier-Crussard A, Reallon E, Mouchoux C, Gervais F. Assessing the prevalence of anticholinergic and sedative medications to avoid in older adults from the French Health Data System. J Am Geriatr Soc. 2025 May;73(5):1542-1550. [PMC free article: PMC12100680] [PubMed: 39749945]

43.

Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002 Jan;53(1):39-49. [PubMed: 11773648]

44.

McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, Gibler WB, Ohman EM, Drew B, Philippides G, Newby LK., American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008 Apr 08;117(14):1897-907. [PubMed: 18347214]

45.

Pribék IK, Kovács I, Kádár BK, Kovács CS, Richman MJ, Janka Z, Andó B, Lázár BA. Evaluation of the course and treatment of Alcohol Withdrawal Syndrome with the Clinical Institute Withdrawal Assessment for Alcohol - Revised: A systematic review-based meta-analysis. Drug Alcohol Depend. 2021 Mar 01;220:108536. [PubMed: 33503582]

46.

Olateju OA, Shrestha M, Altaie A, Varisco TJ, Thornton JD. Effects of the prescription drug monitoring program mandate on queries of controlled substance prescriptions: Findings from Texas. J Am Pharm Assoc (2003). 2025 Jul-Aug;65(4):102402. [PubMed: 40246022]

47.

Sake FT, Wong K, Bartlett DJ, Saini B. Benzodiazepine usage and patient preference for alternative therapies: A descriptive study. Health Sci Rep. 2019 May;2(5):e116. [PMC free article: PMC6529930] [PubMed: 31139756]

48.

Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. BMJ. 1995 Jan 28;310(6974):219-21. [PMC free article: PMC2548618] [PubMed: 7866122]

49.

Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf. 1993 Aug;9(2):93-103. [PubMed: 8104417]

50.

Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]

51.

Parra J, Sancho J, Miranda-Gonzalbo V, Brocalero-Camacho A. [Injury to both internal globus pallidi due to hypoxic encephalopathy as a consequence of respiratory arrest following the consumption of opiates and benzodiazepines]. Rev Neurol. 2007 Feb 16-28;44(4):243-4. [PubMed: 17311215]

52.

Höjer J, Baehrendtz S, Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med. 1989 Aug;226(2):117-22. [PubMed: 2769176]

53.

Höjer J. [Flumazenil--a valuable diagnostic agent in coma but only with clear indications]. Lakartidningen. 1992 Feb 19;89(8):549-50. [PubMed: 1740946]

54.

Spady C, Cannon D, Wongworawat MD, Ruckle DE, Nayak R, McPhee B. Effect of CURES Legislation on Narcotic Prescriptions After Soft-tissue Hand Surgery. J Surg Orthop Adv. 2024 Summer;33(2):122-124. [PubMed: 38995071]

Disclosure: Ravneet Singh declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Sara Abdijadid declares no relevant financial relationships with ineligible companies.